ODAC votes 9-6 in favor of Clolar for pediatric acute lymphoblastic leukemia, but votes against Marqibo for non-Hodgkin’s lymphoma.
Also NCI prostate SPOREs plan biospecimen bank.
NCI advisors seek comment on clinical trials system, until Jan. 15.
NCI funds 17 EDRN biomarker labs. Bush signs omnibus funding legislation.
Dept. of Defense opens program announcements for prostate cancer research.
Children’s Cancer Research Institute at UT Health Science Center recruits faculty.
Two cancer center directors named: Michael Kastan at St. Jude, James Willson at Harold Simmons.
December issue of Business & Regulatory Report included (an additional 8 pages of industry news).
Next issue of The Cancer Letter is scheduled for Jan. 7, 2005.
Trending Stories
- NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - Trump administration is removing the mainstays of NCI and the federal government’s cancer program
Peer review, registries, and evidence-based patient information take a big hit - Bhattacharya cancels NIH all-hands meeting
- Cyber-iconoclast Vinay Prasad named head of FDA’s CBER
An oncologist, Prasad has criticized accelerated approval, next-gen sequencing, and targeted therapies - In the Headlines: “There’s no one to stand up for NCI right now.”
- George Weiner: Cancer centers are special, as are site visits in CCSG review
